Symbols / NUVL
NUVL Chart
About
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 8.04B |
| Enterprise Value | 6.67B | Income | -425.38M | Sales | — |
| Book/sh | 15.96 | Cash/sh | 17.45 | Dividend Yield | — |
| Payout | 0.00% | Employees | 228 | IPO | — |
| P/E | — | Forward P/E | -25.58 | PEG | — |
| P/S | — | P/B | 6.41 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 15.05 |
| Current Ratio | 15.27 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -5.85 | EPS next Y | -4.00 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-07 | ROA | -20.27% |
| ROE | -36.70% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 73.18M |
| Shs Float | 48.73M | Short Float | 15.53% | Short Ratio | 11.34 |
| Short Interest | — | 52W High | 113.02 | 52W Low | 55.53 |
| Beta | 1.32 | Avg Volume | 523.66K | Volume | 484.53K |
| Target Price | $143.53 | Recom | Strong_buy | Prev Close | $99.41 |
| Price | $102.32 | Change | 2.93% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$143.53
Mean price target
2. Current target
$102.32
Latest analyst target
3. DCF / Fair value
$-34.83
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$102.32
Low
$125.00
High
$165.00
Mean
$143.53
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-27 | main | Cantor Fitzgerald | Overweight → Overweight | $140 |
| 2025-12-19 | main | JP Morgan | Overweight → Overweight | $145 |
| 2025-11-24 | init | Truist Securities | — → Buy | $140 |
| 2025-11-18 | main | Goldman Sachs | Buy → Buy | $135 |
| 2025-11-18 | main | Baird | Outperform → Outperform | $158 |
| 2025-11-18 | main | Guggenheim | Buy → Buy | $155 |
| 2025-11-17 | main | Stifel | Buy → Buy | $135 |
| 2025-11-17 | main | Leerink Partners | Outperform → Outperform | $149 |
| 2025-11-17 | main | HC Wainwright & Co. | Buy → Buy | $155 |
| 2025-11-12 | init | Canaccord Genuity | — → Buy | $126 |
| 2025-10-31 | main | Barclays | Overweight → Overweight | $112 |
| 2025-10-31 | main | UBS | Buy → Buy | $132 |
| 2025-10-27 | main | Piper Sandler | Overweight → Overweight | $128 |
| 2025-10-15 | init | Cantor Fitzgerald | — → Overweight | $135 |
| 2025-09-08 | reit | Wedbush | Outperform → Outperform | $115 |
| 2025-09-03 | init | Raymond James | — → Outperform | $105 |
| 2025-08-19 | init | Piper Sandler | — → Overweight | $112 |
| 2025-06-25 | main | Baird | Outperform → Outperform | $112 |
| 2025-06-24 | main | Leerink Partners | Outperform → Outperform | $140 |
| 2025-06-24 | main | HC Wainwright & Co. | Buy → Buy | $130 |
- Assessing Nuvalent (NUVL) Valuation After Wider Losses And A New Shelf Registration - simplywall.st Mon, 09 Mar 2026 23
- (NUVL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily Mon, 09 Mar 2026 13
- Nuvalent Announces Public Offering of Common Stock - PR Newswire Mon, 17 Nov 2025 08
- Lung cancer drug developer Nuvalent now holds $1.4B cash runway to 2029 - Stock Titan hu, 26 Feb 2026 08
- Does Nuvalent (NUVL) Have the Potential to Rally 37.26% as Wall Street Analysts Expect? - Yahoo Finance Fri, 27 Feb 2026 08
- Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat Fri, 20 Feb 2026 08
- Lung cancer drug developer sets 2026 plan as FDA reviews new therapy - Stock Titan Mon, 12 Jan 2026 08
- Nuvalent (NUVL): Assessing an Expensive-Looking Valuation After a Strong Multi-Year Share Price Run - Yahoo Finance ue, 23 Dec 2025 08
- (NUVL) Risk Channels and Responsive Allocation - Stock Traders Daily hu, 26 Feb 2026 11
- Nuvalent Expands Funding Flexibility As Valuation Discount Draws Investor Attention - simplywall.st Sat, 07 Mar 2026 11
- Nuvalent (NASDAQ: NUVL) closes $500M stock offering; 4,950,496 shares sold in public deal - Stock Titan Mon, 24 Nov 2025 08
- Assessing Nuvalent (NUVL) Valuation After Recent Share Price Cooling And Strong Multi Year Returns - simplywall.st Mon, 02 Mar 2026 19
- $NUVL stock is up 14% today. Here's what we see in our data. - Quiver Quantitative Mon, 17 Nov 2025 08
- Nuvalent: Deerfield funds sell $70.8m in NUVL stock - Investing.com Mon, 24 Nov 2025 08
- Nuvalent, Inc. Stock (NUVL) Opinions on Cancer Therapy Developments and Insider Sale - Quiver Quantitative hu, 02 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5500 | 566788 | — | Sale at price 102.64 - 103.96 per share. | MILLER DEBORAH ANN | Officer | — | 2026-02-26 00:00:00 | D |
| 1 | 5500 | 566682 | — | Sale at price 102.64 - 104.25 per share. | NOCI DARLENE | Officer | — | 2026-02-26 00:00:00 | D |
| 2 | 5500 | 37895 | — | Conversion of Exercise of derivative security at price 6.89 per share. | MILLER DEBORAH ANN | Officer | — | 2026-02-26 00:00:00 | D |
| 3 | 5500 | 153175 | — | Conversion of Exercise of derivative security at price 27.85 per share. | NOCI DARLENE | Officer | — | 2026-02-26 00:00:00 | D |
| 4 | 5500 | 561422 | — | Sale at price 100.95 - 103.39 per share. | NOCI DARLENE | Officer | — | 2026-01-29 00:00:00 | D |
| 5 | 5500 | 153175 | — | Conversion of Exercise of derivative security at price 27.85 per share. | NOCI DARLENE | Officer | — | 2026-01-29 00:00:00 | D |
| 6 | 15000 | 1652176 | — | Sale at price 109.84 - 110.16 per share. | MILLER DEBORAH ANN | Officer | — | 2026-01-22 00:00:00 | D |
| 7 | 15000 | 417750 | — | Conversion of Exercise of derivative security at price 27.85 per share. | MILLER DEBORAH ANN | Officer | — | 2026-01-22 00:00:00 | D |
| 8 | 17500 | — | — | Stock Award(Grant) at price 0.00 per share. | TURNER CHRISTOPHER DURANT | Officer | — | 2026-01-07 00:00:00 | D |
| 9 | 17500 | — | — | Stock Award(Grant) at price 0.00 per share. | BALCOM ALEXANDRA | Chief Financial Officer | — | 2026-01-07 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -414.31M | -280.37M | -149.49M | -86.11M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -425.38M | -260.76M | -126.22M | -81.85M |
| EBITDA | -414.31M | -280.37M | -149.49M | -86.11M |
| EBIT | -414.31M | -280.37M | -149.49M | -86.11M |
| NetInterestIncome | 44.73M | 38.32M | 23.27M | 4.25M |
| InterestIncome | 44.73M | 38.32M | 23.27M | 4.25M |
| NormalizedIncome | -425.38M | -260.76M | -126.22M | -81.85M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -425.38M | -260.76M | -126.22M | -81.85M |
| TotalExpenses | 414.31M | 280.37M | 149.49M | 86.11M |
| TotalOperatingIncomeAsReported | -414.31M | -280.37M | -149.49M | -86.11M |
| DilutedAverageShares | 66.41M | 58.22M | 49.67M | 21.78M |
| BasicAverageShares | 66.41M | 58.22M | 49.67M | 21.78M |
| DilutedEPS | -3.93 | -2.17 | -1.65 | -2.13 |
| BasicEPS | -3.93 | -2.17 | -1.65 | -2.13 |
| DilutedNIAvailtoComStockholders | -425.38M | -260.76M | -126.22M | -81.85M |
| NetIncomeCommonStockholders | -425.38M | -260.76M | -126.22M | -81.85M |
| NetIncome | -425.38M | -260.76M | -126.22M | -81.85M |
| NetIncomeIncludingNoncontrollingInterests | -425.38M | -260.76M | -126.22M | -81.85M |
| NetIncomeContinuousOperations | -425.38M | -260.76M | -126.22M | -81.85M |
| TaxProvision | 585.00K | 764.00K | 0.00 | 0.00 |
| PretaxIncome | -424.79M | -259.99M | -126.22M | -81.85M |
| OtherIncomeExpense | -55.22M | -17.94M | 4.25M | -521.00K |
| OtherNonOperatingIncomeExpenses | -55.22M | -17.94M | 4.25M | -521.00K |
| NetNonOperatingInterestIncomeExpense | 44.73M | 38.32M | 23.27M | 4.25M |
| InterestIncomeNonOperating | 44.73M | 38.32M | 23.27M | 4.25M |
| OperatingIncome | -414.31M | -280.37M | -149.49M | -86.11M |
| OperatingExpense | 414.31M | 280.37M | 149.49M | 86.11M |
| ResearchAndDevelopment | 306.97M | 217.77M | 113.24M | 63.73M |
| SellingGeneralAndAdministration | 107.34M | 62.59M | 36.25M | 22.38M |
| GeneralAndAdministrativeExpense | 107.34M | 62.59M | 36.25M | 22.38M |
| OtherGandA | 15.03M | 10.85M | 6.42M | 22.38M |
| InsuranceAndClaims | 28.63M | 9.63M | 6.74M | 5.46M |
| SalariesAndWages | 63.68M | 42.11M | 23.09M | 12.32M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 78.24M | 71.34M | 64.07M | 56.67M |
| ShareIssued | 78.24M | 71.34M | 64.07M | 56.67M |
| TangibleBookValue | 1.25B | 1.07B | 700.56M | 462.98M |
| InvestedCapital | 1.25B | 1.07B | 700.56M | 462.98M |
| WorkingCapital | 1.30B | 1.08B | 694.66M | 458.51M |
| NetTangibleAssets | 1.25B | 1.07B | 700.56M | 462.98M |
| CommonStockEquity | 1.25B | 1.07B | 700.56M | 462.98M |
| TotalCapitalization | 1.25B | 1.07B | 700.56M | 462.98M |
| TotalEquityGrossMinorityInterest | 1.25B | 1.07B | 700.56M | 462.98M |
| StockholdersEquity | 1.25B | 1.07B | 700.56M | 462.98M |
| GainsLossesNotAffectingRetainedEarnings | 2.35M | -59.00K | 31.00K | -494.00K |
| OtherEquityAdjustments | 2.35M | -59.00K | 31.00K | -494.00K |
| RetainedEarnings | -972.43M | -547.05M | -286.30M | -160.08M |
| AdditionalPaidInCapital | 2.22B | 1.62B | 986.82M | 623.54M |
| CapitalStock | 8.00K | 8.00K | 7.00K | 6.00K |
| CommonStock | 8.00K | 8.00K | 7.00K | 6.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 164.37M | 71.96M | 31.82M | 19.48M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 73.19M | 17.94M | 0.00 | 0.00 |
| OtherNonCurrentLiabilities | 35.00K | |||
| DuetoRelatedPartiesNonCurrent | 73.16M | 17.94M | 0.00 | |
| TradeandOtherPayablesNonCurrent | 0.00 | 0.00 | 0.00 | |
| CurrentLiabilities | 91.17M | 54.02M | 31.82M | 19.48M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 16.93M | 10.45M | 7.33M | 4.85M |
| PayablesAndAccruedExpenses | 74.24M | 43.57M | 24.50M | 14.63M |
| CurrentAccruedExpenses | 44.08M | 38.34M | 15.22M | 7.43M |
| Payables | 30.16M | 5.22M | 9.27M | 7.20M |
| AccountsPayable | 30.16M | 5.22M | 9.27M | 7.20M |
| TotalAssets | 1.41B | 1.14B | 732.38M | 482.46M |
| TotalNonCurrentAssets | 20.28M | 9.30M | 5.90M | 4.47M |
| OtherNonCurrentAssets | 20.28M | 9.30M | 5.90M | 4.47M |
| CurrentAssets | 1.39B | 1.13B | 726.49M | 477.99M |
| OtherCurrentAssets | 20.47M | 14.15M | 6.58M | 5.83M |
| PrepaidAssets | 2.52M | |||
| CashCashEquivalentsAndShortTermInvestments | 1.37B | 1.12B | 719.90M | 472.16M |
| OtherShortTermInvestments | 1.11B | 972.61M | 384.52M | 230.36M |
| CashAndCashEquivalents | 261.75M | 145.69M | 335.39M | 241.81M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -275.21M | -185.06M | -99.74M | -64.97M |
| IssuanceOfDebt | 0.00 | 284.00K | ||
| IssuanceOfCapitalStock | 515.72M | 569.99M | 338.48M | 250.47M |
| EndCashPosition | 261.75M | 145.69M | 335.39M | 241.81M |
| BeginningCashPosition | 145.69M | 335.39M | 241.81M | 68.53M |
| ChangesInCash | 116.05M | -189.70M | 93.58M | 173.28M |
| FinancingCashFlow | 515.34M | 568.88M | 336.85M | 248.92M |
| CashFlowFromContinuingFinancingActivities | 515.34M | 568.88M | 336.85M | 248.92M |
| NetOtherFinancingCharges | -382.00K | -1.10M | -1.63M | -1.55M |
| ProceedsFromStockOptionExercised | 14.18M | 1.84M | 12.00K | |
| NetPreferredStockIssuance | 0.00 | 144.65M | ||
| PreferredStockIssuance | 0.00 | 144.65M | ||
| NetCommonStockIssuance | 515.72M | 569.99M | 338.48M | 250.47M |
| CommonStockIssuance | 515.72M | 569.99M | 338.48M | 250.47M |
| NetIssuancePaymentsOfDebt | 0.00 | 284.00K | ||
| NetLongTermDebtIssuance | 0.00 | 284.00K | ||
| LongTermDebtIssuance | 0.00 | 284.00K | ||
| InvestingCashFlow | -124.08M | -573.51M | -143.53M | -10.66M |
| CashFlowFromContinuingInvestingActivities | -124.08M | -573.51M | -143.53M | -10.66M |
| NetInvestmentPurchaseAndSale | -124.08M | -573.51M | -143.53M | -10.66M |
| SaleOfInvestment | 933.69M | 451.45M | 315.96M | 202.25M |
| PurchaseOfInvestment | -1.06B | -1.02B | -459.49M | -212.92M |
| OperatingCashFlow | -275.21M | -185.06M | -99.74M | -64.97M |
| CashFlowFromContinuingOperatingActivities | -275.21M | -185.06M | -99.74M | -64.97M |
| ChangeInWorkingCapital | 19.21M | 11.84M | 11.03M | 6.93M |
| ChangeInOtherCurrentAssets | -10.51M | -3.41M | -1.43M | -1.27M |
| ChangeInPayablesAndAccruedExpense | 36.06M | 22.81M | 11.81M | 9.69M |
| ChangeInAccruedExpense | 11.46M | 26.86M | 9.64M | 5.48M |
| ChangeInPayable | 24.60M | -4.05M | 2.17M | 4.21M |
| ChangeInAccountPayable | 24.60M | -4.05M | 2.17M | 4.21M |
| ChangeInPrepaidAssets | -6.34M | -7.56M | 644.00K | -1.49M |
| OtherNonCashItems | 44.46M | 3.27M | -10.11M | -373.00K |
| StockBasedCompensation | 86.50M | 60.58M | 25.56M | 10.32M |
| AmortizationOfSecurities | -10.11M | -373.00K | 215.00K | |
| NetIncomeFromContinuingOperations | -425.38M | -260.76M | -126.22M | -81.85M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NUVL
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|